Stockreport

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) announced that amlenet [Read more]